Form 4: Aquestive Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Sherry Korczynski, Chief Commercial Officer of Aquestive Therapeutics, Inc., sold 8,750 shares of common stock on September 9, 2026 for $5.22 per share.

Summary

  • Option exercise/conversion: acquired 8,750 Common Stock at $2.65 ($23,188) on September 9, 2026; holds 244,439 after (Direct).
  • Open-market sale: disposed of 8,750 Common Stock at $5.22 ($45,675) on September 9, 2026; holds 235,689 after (Direct).
  • Option exercise/conversion: disposed of 8,750 Non-Qualified Stock Option (right to buy) on September 9, 2026; holds 26,250 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $45,675 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Sherry Korczynski — Officer (Chief Commercial Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-09Option exercise/conversionCommon Stock8,750$3$23.2K244,439
2026-09-09Open-market saleCommon Stock8,750$5$45.7K235,689
2026-09-09Option exercise/conversionNon-Qualified Stock Option (right to buy)8,750——26,250

Key Dates

DateDescription
2026-09-09Option exercise/conversion (8,750 shares)
2026-09-09Open-market sale (8,750 shares)
2026-09-09Option exercise/conversion (8,750 shares)

Keywords

insider transaction, Form 4, AQST, Aquestive Therapeutics, Inc., bearish, Sherry Korczynski

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.